The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Peel Hunt today reaffirms its buy investment rating on Eco Animal Health Group PLC (LON:EAH) and cut its price target to 460p (from 600p). It would be nice if it could recover that level but there is much restoration to do.
Sasa, today's fall was a complete over-reaction to disappointing news. The SP has recovered to to 30% down from 54% down so I think the initial drop was just a case of overkill by the MM's. I was tempted to cut my losses but saw the recovery well under way early morning. The company is performing well in Brazil, Mexico and India which ia awewmingly lost in the noise around China. I am quite happy that I didnt jump ship like I was tempted to and although I will see a loss in this share I think I can at least have some damage limitation.
today's RNS is - a dramatic fall off in Chinese demand and also accounting difficulties just to exacerbate the problems - too much for me to run on with 'walking wounded' in these problematic mkts, so I'm 'outa here' on the premise that 'the first cut is often the cheapest' - sasa.
This bb seems to be all but dead; only ericeric and I seem to follow this periodically.
The next results, hopefully, will garner some interest in this near unique share. I notice that one broker has consistently rated EAH a firm 'buy' with a t/p of 725p which would be nice to see it move higher from here even part of the way towards that sort of level - hope springs....sasa.
This time from the EU to distribute Aviolosin across Europe - can only be positive for EAH but still it doesn't move the sp - this is becoming increasingly overlooked / cheap this share - sasa.
With another US collaborative agreement - can't be bad, although the sp doesn't seem to notice,,,sasa.
"Not a bad company, the current valuation makes the shares expensive though" It's an excellent company and the shares are far from expensive when viewed by a potential bidder- a much bigger company with its own sales forces who could make a much bigger profit margin than Eco is able to do via distributors.
I wonder what happened to the various deals which I know took place between 0800 and 0810 this morning, including one of my own? They were visible in the LSE share trades list earlier but are now gone. Something to do with the obvious problems LSE has had today with their systems, resulting in very slow web access speeds? I hope they're not running Windows XP...
To take you away from the share chat am running the London marathon on the 23 April for the animal hope and wellness foundation that save dogs/cats from being tortured in the dog/cat meat Asian meat trade even if all you can afford is £1 it would be GREATLY APPRECIATED please donate at Neil beedie just give thank you :)
Not a bad company, the current valuation makes the shares expensive though
'' I look forward with confidence to reporting another set of strong results in 2017.” '' GREAT and STRONG results
22% increase in sales to £39.0 million ( +28% at constant exchange rates ) 23% increase in gross profit to £17.4 million with gross profit margin held at 45% 22% increase in adjusted EBITDA to £8.6 million ( +35% at constant exchange rates) 13% increase in total dividend for the year to 4.75p with second interim dividend of 3.0p Cash generation from operations up 16% to £7.2 million Pre-tax profit up 38% to £5.1 million Net cash of £17.7m
I wonder did Schroders offload some into the recent rise? I have been tracking these and waiting. i would love a retrace here to get in, having watched them rise while sitting on my hands.
24 February 2014 ECO Animal Health Group plc (AIM: EAH) ECO RECEIVES FIRST MARKETING AUTHORISATION FOR AIVLOSIN® IN THE REPUBLIC OF KOREA ECO is pleased to announce that it has received a marketing authorisation for Aivlosin® 42.5 mg/g premix for swine from the Animal and Plant Quarantine Agency of the Republic of Korea. The product will be marketed for the treatment of swine respiratory disease caused by Mycoplasma hyopneumoniae underECO's Valosin® trade name in this territory. ECO has a long standing relationship with a South Korean distributor who assisted in obtaining this marketing authorisation. Launch plans are well advanced and is expected to take place within a couple of months. Pork production is the largest agricultural sector after rice in South Korea, which produces almost one million metric tons of pork every year, with consumption increasing faster than any other type of meat. Aivlosin®, ECO's patented macrolide antibiotic, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry. Peter Lawrence, Chairman of ECO, commented "This authorisation in the Republic of Korea is another encouraging and positive step in the development of Aivlosin® as a fast growing, truly global brand. It underlines ECO's continued commitment to being a major force in the international market for veterinary pharmaceutical products." Contacts: ECO Animal Health Group plc Marc Loomes 020 8447 8899 Spiro Financial Anthony Spiro 020 8336 6196 Cenkos Securities plc Stephen Keys 020 7397 8926 (Nominated Adviser) ECO Animal Health Gr
28 October 2013 ECO Animal Health Group plc ("ECO" or "the Company") (AIM:EAH) ECO RECEIVES POSITIVE OPINION ON AIVLOSIN® FOR TURKEYS IN EUROPE ECO is pleased to announce that it has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g water soluble granules in turkeys. This positive opinion will allow for the medication of drinking water with Aivlosin® for the treatment of respiratory disease associated with Ornithobacteriumrhinotracheale (ORT) in turkeys. Aivlosin® is the first antibiotic to be granted approval in Europe for this specific indication, an economically important respiratory disease. Europe has a 30 per cent share of global turkey meat production. Aivlosin®, ECO's patented macrolide antibiotic, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry. Peter Lawrence, Chairman, commented "This positive opinion from the EMA is a further encouraging step in the development of Aivlosin® as a truly global, multi-species, versatile brand that treats a multitude of different diseases. It underlines ECO's commitment to be a major force in the global market for animal health products." Contacts: ECO Animal Health Group plc Peter Lawrence 020 8336 6190 Spiro Financial 020 8336 6196 Cenkos Securities plc (Nominated Adviser) Stephen Keys 020 7397 8926 ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for the global markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders. Eco Animal Health Group Plc
Correction - trade price was 190p and not 199p. Waiting for the pain of Wednesday.... which is the settlement day for my recent purchase at 196p. Should be an interesting chat with the broker.....
Looks like a 2.1M trade went through at 199p at close of play just before 7,053,385 new ordinary shares are admitted to trading on AIM at 8.00 am tomorrow. The previous shares were 64,330K. So expecting a 10% correction tomorrow for the dilution. Oh joy! The only movement through dilution....
Trying out a new low cost advisory-broker and have just bought in at 196p+Stamp +dealing costs (£20in/£20out). Need to see 260p to cover costs and realise my target +25%. Let's see how this broker works out......
Top Director Sells ECO Animal Health Group (EAH) Director name: Mr Peter Lawrence Amount sold: 59,640 @ 240.00p Value: £143,136
Unpredictable timing of orders in Latin America affects sales"The success of this strategy is reflected in overall sales in the period of £11.45m (2011: £11.88m) which were a little lower than last year's level, mainly due to Latin America where the timing of orders, coupled with the availability of foreign currency can be unpredictable but, in the medium term these issues have tended to unwind. Nevertheless, these factors were more than outweighed by the significant improvement in margin and gross profit." He added: "The second half of the year is traditionally a stronger trading period as the incidence of respiratory disease increases and parasite numbers rise during the southern hemisphere spring and it is pleasing to note that our performance in the first two months of the second half has been strong. These traditional factors, coupled with the exciting sales opportunities offered by our entry into new markets for Aivlosin in Canada, the USA and Russia, enable us to look forward with confidence and we expect to deliver another sound full year result for our shareholders."
AIM-listed ECO Animal Health Group reported a slight reduction in its revenue for the six month period ending September 30th, according to the group's half yearly report. The company, which develops pharmaceutical products for the global animal health markets, stated that its revenue was £11.46m compared to £11.88m for the corresponding period last year. Gross profit rose 14.7% to £5.1m and earnings before interest, tax, depreciation, amortisation, share based payments and foreign exchange movements, amounted to £2.0m. This was less than the £2.3m generated in the same period in 2011, but reflected product launch costs of £0.3m in the US and Canada. Peter Lawrence, Executive Chairman of the group, said: "In the light of the many new opportunities opening up to the group, we are concentrating our management and financial resources on those products and markets with the greatest potential for profitable growth and reducing exposure to those with limited margins and restricted growth potential.
Peter Lawrence, Chairman of ECO, commented “This latest authorisation in Russia is another extremely encouraging and positive step in the development of Aivlosin® as a truly global brand and underlines ECO’s commitment to becoming a major force in the international market for veterinary pharmaceutical products.”
CO RECEIVES FIRST MARKETING AUTHORISATION FOR AIVLOSIN® IN RUSSIA ECO is pleased to report that the Ministry of Agriculture of the Russian Federation has granted ECO a marketing authorisation for Aivlosin® 42.5 mg/g premix for swine. Russia is the seventh largest pork producing country and it has seen a 50 per cent growth in pork production between 2006 and 2011 driven by both domestic demand and import substitution, with growing adoption of large scale, intensive production techniques. This initial and very important Russian authorisation comes just four months after the US Food and Drug Administration granted ECO its first marketing authorisation in the United States for Aivlosin® 625 mg/g water soluble granules for swine. Aivlosin®, ECO’s patented macrolide antibiotic, is used for the treatment of respiratory and enteric (gut) diseases in pigs and poultry.
OUTLOOK We are confident that the long awaited marketing authorisations in the US and Canada will have a major positive effect on the development of ECO, although it will be some months before the product launches gain momentum. We do not expect a noticeable impact on our financial performance until next year. ECO is very well placed to further broaden its product ranges and its global spread will ensure that it capitalises on opportunities as they arise in all the Group’s major markets. The Group is set for an exciting future and looks forward to maximising value for shareholders.